Vineet Laborator

What does Vineet Laborator do?

Vineet Laboratories Ltd is a micro-cap manufacturing company that produces intermediates for active pharmaceutical ingredients, incorporated in 2016. As of March 2025, it reported net sales of 14 Cr and a net loss of 11 Cr.

Overview:<BR>Vineet Laboratories Ltd is a manufacturing company specializing in intermediates for the production of active pharmaceutical ingredients, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap.<BR><BR>History:<BR>Vineet Laboratories Ltd was incorporated on 10 November 2016, previously known as Ortin Laboratories Limited. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 14 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: -11 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 30 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 1.55 <BR>Return on Equity: -80.61% <BR>Price to Book: 1.18<BR><BR>Contact Details:<BR>Address: SyNo 11/A3 Saheb Nagar KurduVi, Chintal Kunta Eshwaramma LB Nr Hyderabad Telangana : 500074 <BR>Tel: 91-40-24128833 <BR>Email: cs@vineetlabs.co.in <BR>Website: http://www.vineetlaboratories.com

Has Vineet Laborator declared dividend?

Yes, Vineet Laboratories Ltd has declared a 10% dividend, amounting to 1 per share, with an ex-date of September 19, 2022. However, the company has experienced significant price declines over various periods, resulting in minimal total returns.

Vineet Laboratories Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: 19 Sep 22<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -41.27%, the dividend return was 0%, resulting in a total return of -41.27%.<BR><BR>For the 1-year period, the price return was -45.93%, the dividend return was 0%, leading to a total return of -45.93%.<BR><BR>Over the 2-year period, the price return was -37.8%, the dividend return was 0%, which resulted in a total return of -37.8%.<BR><BR>In the 3-year period, the price return was -49.94%, the dividend return was 1.71%, culminating in a total return of -48.23%.<BR><BR>For the 4-year period, the price return was 0%, the dividend return was 1.78%, resulting in a total return of 1.78%.<BR><BR>In the 5-year period, the price return was 0%, the dividend return was 0%, leading to a total return of 0.0%.<BR><BR>Overall, while Vineet Laboratories Ltd has declared a dividend, the total returns over various periods indicate significant declines in price, with only modest positive returns in the longer-term periods. The absence of substantial dividend returns in most periods suggests a challenging financial performance.

Who are the peers of the Vineet Laborator?

Vineet Laborator's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Colinz Labs, Zenith Health, Ishita Drugs, Chemo Pharma Lab, and Phaarmasia. Vineet Laborator has below-average management risk and growth, with a significant negative return of -46.35% over the past year compared to its peers.

Peers: The peers of Vineet Laborator are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Colinz Labs, Zenith Health, Ishita Drugs, Chemo Pharma Lab, and Phaarmasia.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at Vineet Laborator. Below Average management risk is noted for Colinz Labs, Zenith Health, Ishita Drugs, and Phaarmasia. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Vineet Laborator, Divi's Lab., Torrent Pharma, Colinz Labs, Zenith Health, Ishita Drugs, and Phaarmasia. Capital Structure is Excellent at Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, Good at Torrent Pharma and Colinz Labs, while Below Average is noted for Vineet Laborator and Phaarmasia, and the rest have Good capital structures.<BR><BR>Return Snapshot: Colinz Labs has the highest 1-year return at 66.49%, while Vineet Laborator has the lowest at -46.35%, indicating a significant negative performance compared to its peers. Additionally, Vineet Laborator, Torrent Pharma, and Phaarmasia have negative six-month returns.

Is Vineet Laborator overvalued or undervalued?

As of November 14, 2024, Vineet Laborator is considered overvalued with a PE ratio of -1.44 and an EV to EBITDA of -4.18, indicating significant financial distress compared to peers like Cipla and Dr. Reddy's, and has underperformed the Sensex with a year-to-date return of -50.28%.

As of 14 November 2024, Vineet Laborator has moved from a very attractive to a risky valuation grade. The company is currently considered overvalued, with a price-to-earnings (PE) ratio of -1.44, an EV to EBITDA ratio of -4.18, and a return on equity (ROE) of -80.61%. These figures indicate significant financial distress and a lack of profitability, which are concerning for potential investors.<BR><BR>In comparison to its peers, Vineet Laborator's valuation metrics starkly contrast with companies like Cipla Ltd., which has a PE ratio of 22.99 and an EV to EBITDA of 15.93, and Dr. Reddy's Laboratories Ltd., with a PE of 19.49 and an EV to EBITDA of 12.87. The substantial differences in these ratios highlight the challenges Vineet Laborator faces in the current market. Additionally, the company's stock has underperformed significantly compared to the Sensex, with a year-to-date return of -50.28% against the Sensex's 5.58%, further reinforcing the notion that Vineet Laborator is overvalued at its current price of 31.00.

What is the technical trend for Vineet Laborator?

As of May 30, 2025, Vineet Laborator's technical trend is mildly bearish, with mixed signals from indicators like the weekly MACD being mildly bullish and daily moving averages remaining bearish.

As of 30 May 2025, the technical trend for Vineet Laborator has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD shows a mildly bearish trend. The Bollinger Bands are also signaling mildly bearish on both weekly and monthly time frames. Daily moving averages remain bearish, suggesting short-term weakness. The KST is mildly bullish on the weekly chart but bearish on the monthly, indicating mixed signals. Overall, the current technical stance is mildly bearish, with key indicators such as the daily moving averages and Bollinger Bands contributing to this outlook.

Who are in the management team of Vineet Laborator?

As of March 2021, the management team of Vineet Laborator includes Gaddam Venkata Ramana (Managing Director), Bhupathiraju S Raju (Whole Time Director & CFO), Kandula Murali Mohan (Non Executive Director), Dilip V Acharekar and K. Bhaskar Reddy (Independent Directors), Nirosha Ravikanti (Company Secretary), Yerukalapudi Hari Priya (Additional Director), and Rameshkumar Bandari (Company Secretary & Compliance Officer). Each member contributes to the company's governance and management.

As of March 2021, the management team of Vineet Laborator includes the following individuals:<BR><BR>1. Gaddam Venkata Ramana - Managing Director<BR>2. Bhupathiraju S Raju - Whole Time Director & CFO<BR>3. Kandula Murali Mohan - Non Executive Director<BR>4. Dilip V Acharekar - Independent Director<BR>5. K. Bhaskar Reddy - Independent Director<BR>6. Nirosha Ravikanti - Company Secretary<BR>7. Yerukalapudi Hari Priya - Additional Director<BR>8. Rameshkumar Bandari - Company Secretary & Compliance Officer<BR><BR>Each member plays a specific role in the governance and management of the company.

Who are the top shareholders of the Vineet Laborator?

The top shareholders of Vineet Laborator are Venkata Ramana Gaddam, the promoter with 9.01%, and Rajesh Poddar, the highest public shareholder with 4.48%. Individual investors hold a combined 58.67%, with no institutional or pledged promoter holdings.

The top shareholders of Vineet Laborator include Venkata Ramana Gaddam, who is the promoter with the highest holding at 9.01%. The highest public shareholder is Rajesh Poddar, holding 4.48%. Additionally, individual investors collectively hold a significant portion of 58.67%. There are no institutional holdings from mutual funds or foreign institutional investors, and there are no pledged promoter holdings.

How big is Vineet Laborator?

As of 24th July, Vineet Laboratories Ltd has a market capitalization of 28.00 Cr and reported Net Sales of 58.58 Cr, with a Net Profit loss of 18.94 Cr over the latest four quarters. Shareholder's Funds are valued at 34.72 Cr, and Total Assets amount to 116.87 Cr.

As of 24th July, Vineet Laboratories Ltd has a market capitalization of 28.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Vineet Laboratories reported Net Sales of 58.58 Cr. However, the company experienced a loss of 18.94 Cr in Net Profit during the same period.<BR><BR>The latest annual reporting period for the balance sheet is March 2024. Shareholder's Funds are valued at 34.72 Cr, while Total Assets amount to 116.87 Cr.

Are Vineet Laborator latest results good or bad?

Vineet Laboratories' latest results show a mixed performance: while the company achieved a net profit of ₹0.40 crore and improved operating margins, it faced an 8.12% year-on-year revenue decline and significant financial challenges, including a negative return on equity and high debt levels, indicating caution for investors.

The latest results for Vineet Laboratories present a mixed picture. On the positive side, the company reported a net profit of ₹0.40 crore in Q2 FY26, a significant turnaround from a loss of ₹0.87 crore in the previous quarter. Additionally, the operating margin improved dramatically to 18.25%, up from just 4.30% in Q1 FY26, indicating some operational efficiency gains.<BR><BR>However, there are significant concerns. Revenue for the quarter was ₹17.42 crore, which represents an 8.12% decline year-on-year, continuing a troubling trend of decreasing sales. This follows an even steeper drop of 68.82% in the previous quarter. The company's financial health is also worrying, with a return on equity that has plummeted to -137.05%, indicating severe capital inefficiency.<BR><BR>Moreover, the company has faced substantial operational challenges, including a sharp decline in shareholder funds and high financial leverage, with a debt-to-equity ratio of 2.82. The recent reduction in promoter shareholding from 35.85% to 15.89% raises red flags about insider confidence in the company's future.<BR><BR>In summary, while there are some positive signs in terms of profitability and margin recovery, the overall financial performance, particularly the declining revenues and structural challenges, suggest that the results are more concerning than encouraging. Investors should approach with caution given the broader issues at play.

How has been the historical performance of Vineet Laborator?

Vineet Laborator has experienced a significant decline in financial performance, with net sales dropping from 243.48 Cr in March 2021 to 75.00 Cr in March 2025, resulting in a loss of 20.19 Cr after tax. Despite a slight recovery in cash flow from operating activities, the overall financial position remains weak.

Answer:<BR>The historical performance of Vineet Laborator shows a significant decline in key financial metrics over the past few years, culminating in a challenging fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Vineet Laborator's net sales have decreased from 243.48 Cr in March 2021 to just 75.00 Cr in March 2025, reflecting a downward trend in revenue. The total operating income followed a similar pattern, dropping from 243.48 Cr in March 2021 to 75.00 Cr in March 2025. The company's total expenditure, excluding depreciation, also decreased from 235.33 Cr in March 2021 to 91.28 Cr in March 2025, yet the operating profit (PBDIT) turned negative, showing a loss of 16.28 Cr in March 2025 compared to a profit of 8.15 Cr in March 2021. This resulted in a profit before tax of -20.78 Cr in March 2025, down from 4.06 Cr in March 2021, and a profit after tax of -20.19 Cr, contrasting with a profit of 1.78 Cr in March 2021. The company's total liabilities decreased from 108.74 Cr in March 2021 to 94.54 Cr in March 2025, while total assets also fell from 108.74 Cr to 94.54 Cr in the same period. Cash flow from operating activities showed a positive cash flow of 11.00 Cr in March 2025, a recovery from negative cash flows in previous years, but the overall cash position remained weak with no cash equivalents reported at the end of March 2025.

When is the next results date for Vineet Laboratories Ltd?

The next results date for Vineet Laboratories Ltd is 14 February 2026.

The next results date for Vineet Laboratories Ltd is scheduled for 14 February 2026.

Should I buy, sell or hold Vineet Laboratories Ltd?

Which are the latest news on Vineet Laborator?

Why is Vineet Laboratories Ltd falling/rising?

As of 08-May, Vineet Laboratories Ltd's stock price is at 39.50, down 0.48% after a trend reversal. Despite a strong performance over the past month and year, recent declines are attributed to underperformance relative to its sector and decreased investor participation.

As of 08-May, Vineet Laboratories Ltd's stock price is currently at 39.50, reflecting a decrease of 0.19, or 0.48%. This decline comes after a trend reversal, as the stock has fallen following two consecutive days of gains. Additionally, the stock has underperformed its sector by 0.44% today, indicating a weaker performance relative to its peers.<BR><BR>Despite the recent decline, Vineet Laboratories has shown strong performance over various time frames, with a notable increase of 22.63% over the past month and an impressive 108.20% rise over the past year. However, there are signs of falling investor participation, as the delivery volume on 07 May dropped by 52.95% compared to the 5-day average, which may contribute to the stock's current downward movement.<BR><BR>On a technical note, the stock is trading above its moving averages across multiple time frames, suggesting a generally positive long-term trend. However, the combination of today's underperformance, the recent trend reversal, and decreased investor participation are key factors contributing to the stock's current decline.